USE OF DEXPRAMIPEXOLE FOR THE TREATMENT OF MODERATE TO SEVERE ASTHMA
Disclosed herein are methods of treating moderate to severe asthma of the eosinophilic phenotype in a human subject in need thereof with a daily dose of about 75 mg to about 300 mg of dexpramipexole or pharmaceutical acceptable salt thereof, and treating severe asthma of the eosinophilic phenotype in a human subject in need thereof with a daily dose of about 150 mg to about 300 mg of dexpramipexole or pharmaceutical acceptable salt thereof.
1 - 72 . (canceled)
73 . A method of improving the mean forced expiratory volume in 1 second (FEV 1 ) in a human subject in need thereof comprising orally administering to the subject from about 75 mg to about 300 mg of dexpramipexole or a pharmaceutically acceptable salt thereof.
74 . The method of claim 73 , wherein FEV 1 is increased by about 5% to about 10% following administration.
75 . The method of claim 73 , wherein FEV 1 is increased by about 10% to about 20% following administration.
76 . The method of claim 73 , wherein dexpramipexole or a pharmaceutically acceptable salt thereof is administered once daily.
77 . The method of claim 73 , wherein dexpramipexole or a pharmaceutically acceptable salt thereof is administered twice per day.
78 . The method of claim 73 , wherein dexpramipexole or a pharmaceutically acceptable salt thereof is administered at a daily dose of about 150 mg/day.
79 . The method of claim 73 , wherein dexpramipexole or a pharmaceutically acceptable salt thereof is administered at a daily dose of about 300 mg/day.
80 . The method of claim 78 , wherein dexpramipexole or a pharmaceutically acceptable salt thereof is administered at a dose of about 75 mg twice per day.
81 . The method of claim 79 , wherein dexpramipexole or a pharmaceutically acceptable salt thereof is administered at a dose of about 150 mg twice per day.
82 . A method of treating human disease with an eosinophilic phenotype in a human subject in need thereof comprising orally administering to the subject from about 75 mg to about 300 mg of dexpramipexole or a pharmaceutically acceptable salt thereof.
83 . The method of claim 82 , wherein the method results in a reduction of the level of blood absolute eosinophil counts in the subject compared to the level prior to the administration of dexpramipexole to the subject.
84 . The method of claim 82 , wherein the level of blood absolute eosinophil counts in the subject is reduced by about 90%.
85 . The method of claim 82 , wherein the level of blood absolute eosinophil counts in the subject is reduced by about 80%.
86 . The method of claim 82 , wherein the level of blood absolute eosinophil counts in the subject is reduced by about 70%.
87 . The method of claim 82 , wherein the level of blood absolute eosinophil counts in the subject is reduced by about 60%.
88 . The method of claim 82 , wherein the level of blood absolute eosinophil counts in the subject is reduced by about 50%.
89 . The method of claim 82 , wherein dexpramipexole or a pharmaceutically acceptable salt thereof is administered once daily.
90 . The method of claim 82 , wherein dexpramipexole or a pharmaceutically acceptable salt thereof is administered twice per day.
91 . The method of claim 82 , wherein dexpramipexole or a pharmaceutically acceptable salt thereof is administered at a daily dose of about 150 mg/day.
92 . The method of claim 82 , wherein dexpramipexole or a pharmaceutically acceptable salt thereof is administered at a daily dose of about 300 mg/day.
93 . The method of claim 91 , wherein dexpramipexole or a pharmaceutically acceptable salt thereof is administered at a dose of about 75 mg twice per day.
94 . The method of claim 92 , wherein dexpramipexole or a pharmaceutically acceptable salt thereof is administered at a dose of about 150 mg twice per day.
95 . A method of reducing an exacerbation rate in a human subject exhibiting an eosinophilic phenotype comprising orally administering to the subject from about 75 mg to about 300 mg of dexpramipexole or a pharmaceutically acceptable salt thereof.
96 . The method of claim 95 , wherein the exacerbation rate is reduced to less than 2 per year.
97 . The method of claim 95 , wherein dexpramipexole or a pharmaceutically acceptable salt thereof is administered once daily.
98 . The method of claim 95 , wherein dexpramipexole or a pharmaceutically acceptable salt thereof is administered twice per day.
99 . The method of claim 95 , wherein dexpramipexole or a pharmaceutically acceptable salt thereof is administered at a daily dose of about 150 mg/day.
100 . The method of claim 95 , wherein dexpramipexole or a pharmaceutically acceptable salt thereof is administered at a daily dose of about 300 mg/day.
101 . The method of claim 99 , wherein dexpramipexole or a pharmaceutically acceptable salt thereof is administered at a dose of about 75 mg twice per day.
102 . The method of claim 100 , wherein dexpramipexole or a pharmaceutically acceptable salt thereof is administered at a dose of about 150 mg twice per day.